Hazard - P - B - T - Risk Exempt
This summary information comes from previously published text in Fass. Arzerra (ofatumumab) is now withdrawn from use in Sweden since 2019-02-28.
Fass environmental information for Arzerra from Novartis (downloaded 2019-04-24).
The use of amino acids, proteins and peptides is not considered to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm